Foundayo (Orforglipron) Medication Guide
Medication evidence and practical access information. We have no verified affiliate offer for this exact medication; the guide below is informational, not a provider availability claim.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
No verified affiliate offer for this medication
This means we have not verified a supplied affiliate link to a page offering this exact medication—not that the medication is unavailable everywhere. We do not substitute another treatment or a general provider homepage.
The FDA approved Foundayo (orforglipron) on April 1, 2026 for chronic weight management in eligible adults. In the 72-week ATTAIN-1 trial, 36 mg once daily produced −11.2% mean body-weight change by the treatment-regimen estimand and −12.4% by the efficacy estimand. No provider-specific Foundayo affiliate offer has been verified for this guide.
Foundayo is the FDA-approved brand name for orforglipron, a small-molecule GLP-1 receptor agonist taken orally once daily. The FDA prescribing information is the source for labeled administration, dose escalation, contraindications, and warnings.
Foundayo is approved with a reduced-calorie diet and increased physical activity for adults with obesity or adults with overweight and at least one weight-related comorbid condition. A licensed clinician should determine whether it is appropriate based on medical history, contraindications, other medicines, and treatment goals.
ATTAIN-1 randomized adults without diabetes to once-daily orforglipron 6 mg, 12 mg, or 36 mg, or placebo, for 72 weeks. At 36 mg, mean body-weight change was −11.2% versus −2.1% with placebo by the treatment-regimen estimand; the efficacy-estimand result was −12.4%. Those estimands are distinct, and the trial was not a head-to-head comparison with injectable medicines.
Verified Offers for get
What Foundayo Is
Orforglipron is a small-molecule GLP-1 receptor agonist taken as a once-daily oral pill. The FDA prescribing information is the source for labeled administration, dosing, warnings, and contraindications.
FDA approval does not establish that a particular telehealth offer is available or appropriate. This educational guide does not verify individual providers, prices, affiliate destinations, or insurance-navigation services for Foundayo.
What the ATTAIN-1 Trial Showed
The ATTAIN-1 Phase 3 trial randomized 3,127 adults with obesity or overweight without diabetes to once-daily orforglipron 6 mg, 12 mg, or 36 mg, or placebo, for 72 weeks.
At 36 mg, mean body-weight change at week 72 was −11.2% by the treatment-regimen estimand and −12.4% by the efficacy estimand. These are distinct analyses, and ATTAIN-1 did not compare orforglipron directly with injectable semaglutide or tirzepatide.
Access and Clinical Follow-Up
The FDA approval announcement describes Foundayo’s approved chronic-weight-management use with a reduced-calorie diet and increased physical activity in eligible adults.
Before pursuing a prescription, confirm the exact product and dose, dispensing pharmacy, total cost, coverage requirements, contraindications, adverse-effect follow-up, and how to contact the clinical team. A licensed prescriber should make individualized treatment decisions.
What the Studies Actually Show
The clinical figures below are from ATTAIN-1 and distinguish the treatment-regimen and efficacy estimands. FDA approval and label information are linked in the guide text.
| Endpoint | Finding |
|---|---|
| Mean body-weight change at 72 weeks (ATTAIN-1, treatment-regimen estimand)1 | −11.2% with orforglipron 36 mg once daily vs −2.1% with placebo in adults with obesity without diabetes. |
| Mean body-weight change at 72 weeks (ATTAIN-1, efficacy estimand)1 | −12.4% with orforglipron 36 mg once daily. This estimand assumes participants remained on assigned treatment without prohibited weight-management treatment. The efficacy and treatment-regimen estimands answer different questions and should not be treated as interchangeable figures. |
Frequently Asked Questions
What is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist. The FDA approved it on April 1, 2026 for chronic weight management, with a reduced-calorie diet and increased physical activity, in eligible adults.
How did Foundayo perform in ATTAIN-1?
In the 72-week ATTAIN-1 trial, 36 mg once daily produced −11.2% mean body-weight change by the treatment-regimen estimand and −12.4% by the efficacy estimand. The analyses answer different questions and should not be combined.
How is Foundayo different from Wegovy or Zepbound?
Foundayo is a daily pill that may be taken with or without food, whereas Wegovy and Zepbound are injections; Zepbound is also a dual GIP/GLP-1 agonist. ATTAIN-1 was not a direct head-to-head trial with either medicine, so separate-trial results cannot establish which treatment is better for an individual.
Where can I obtain Foundayo?
This guide does not verify provider-specific Foundayo affiliate offers, current cash prices, or dispensing availability. Confirm the exact product, pharmacy, total cost, coverage, and follow-up plan directly with a licensed prescriber, dispensing pharmacy, and insurer.
What are the side effects of Foundayo?
Review the FDA prescribing information with a clinician for adverse reactions, boxed warning, contraindications, and individualized monitoring.
- ATTAIN-1 — NEJM 2025 · Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393:1796–1806.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.